Exhibit 99.1
De novo proteins for immunotherapy January 2020
Forward Looking Statements Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin’s business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates, the sufficiency of its cash resources and other statements containing the words “anticipate,” “believe,” “expect,” “may,” “plan,” “project,” “potential,” “will,” “would,” “could,” “continue,” and similar expressions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, the adequacy of any clinical models, uncertainties associated with regulatory review of clinical trials; our ability to identify or acquire additional clinical candidates, our ability to obtain and maintain regulatory approval for any product candidates and the potential safety, efficacy or clinical utility of or any product candidates, and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form10-Q for the quarter ended September 30, 2019 as filed with the Securities and Exchange Commission. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company is contained in its Quarterly Report on Form10-Q for the quarter ended September 30, 2019, and subsequent reports, filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. © 2020 Neoleukin Therapeutics. All Rights Reserved. Do not distribute or reproduce 2
Leader in De Novo Protein Design for Immunotherapy Neoleukin Therapeutics (NASDAQ: NLTX) founded in 2018; merged with Aquinox Pharmaceuticals to become public company in August 2019 Closedfollow-on offering in December 2019 Platform technology utilizes computational methods for de novo protein design of NeoleukinTM cytokine mimetics Lead program:NL-201, a highly potent,non-alpha, agonist ofIL-2 andIL-15 receptors for cancer immunotherapy Headquarters in Seattle; 39 employees © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 3
Leadership Team Jonathan Drachman, M.D. Kamran Alam Daniel-Adriano Silva, Ph.D. Chief Executive Officer Chief Financial Officer (Interim) VP, Head of Research Previous: CMO, EVP R&D, Previous: CFO Aquinox Previous: Translational Investigator, Seattle Genetics IPD, UW Carl Walkey, Ph.D. Umut Ulge, M.D., Ph.D. Leslie Aberman, J.D. Samantha Willing VP, Corporate Development VP, Translational Medicine VP, IP & Legal Affairs VP, People Previous: Postdoctoral Fellow, Previous: Postdoctoral Fellow, Previous: IDRI, Previous: Seattle Genetics, IPD, UW UW Seattle Genetics Microsoft © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 4
Board of Directors Jonathan G. Drachman, M.D. Todd Simpson Cantey Boyd Director Lead Independent Director Director CEO and President, CFO Managing Director, Neoleukin Therapeutics Seattle Genetics Baker Brothers Advisors Sarah Noonberg, M.D. Lewis T. Williams, M.D., Ph.D. Sean Nolan Director Director Director Previous: CMO, Nohla Therapeutics CEO Walking Fish Therapeutics Previous: CEO, AveXis Previous: CEO, FivePrime Therapeutics 5 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
Functional De Novo Proteins: Better Immunotherapies by Design Computational algorithms invented by Daniel-Adriano Silva at UW IPDNL-201:IL-2/IL-15 cytokine mimetic (Neoleukin™) for cancer immunotherapy Discovery published in Nature January 2019 Company formed to advance technology platform and lead asset © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 6
Neoleukin Therapeutics: Pioneers in De Novo Protein Design Technology originated at University of Washington’s Institute for Protein Design, led by David Baker, PhD Scientific founders are world leaders in de novo protein design Exclusive license obtained for commercialization ofNL-201 and other de novo protein assets Investigating additional NeoleukinTM cytokine mimetics for cancer, inflammation, and autoimmunity © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 7
The Good and Bad ofInterleukin-2(IL-2) Immunotherapy✅IL-2 one of the few immunology drugs proven to work as single-agent ✅Stimulates T cells to fight cancer✅rhIL-2 (Proleukin®) approved for RCC and melanoma â—‹ Durable remissions in5-8% of patients âŒVascular leak syndrome, cytokine storm are frequent side effects âŒTreatment administered in hospital due to significant toxicity âŒLow doses generally insufficient for activity © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 8
IL-2 Binds Strongly toNon-Target Cells, Causing Toxicity and Limiting EfficacyIL-2IL-2IL-2 á â â É£ É£Off-Target Cells Effector T Cell Toxicity & Less Antitumor activity Efficacy © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 9
Building a NeoleukinTM Cytokine Mimetic in 4 Steps Step 1: Step 2: Step 3: Step 4: Develop an accurate Identify regions of Design an idealized Identify optimal structural model of intermolecular topology amino acid sequence the target contact © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 10
Crystal Structure ShowsNeo-2/15 BindingIL-2Râ/É£ as PredictedNeo-2/15 há (CD25)hIL-2 hâ hÉ£Co-crystal structure ofIL-2Co-crystal structureNeoleukin-2/15 Source: Silva et al. Nature, 565,186-191 (2019) (14% linear sequence identity) 11 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
Neo-2/15 BindsIL-2Rβ/É£ Without Detectable Binding toIL-2Rα In VitroNeo-2/15 á â É£ Concentration (M) 12 Source: Silva et al. Nature, 565,186-191 (2019) © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
Neo-2/15 Is More Active thanIL-2 in CT26 Murine Colon Cancer Model mor cell implantationNeo-2/15Neo-2/15 13 Source: Silva et al. Nature, 565,186-191 (2019) © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
Neo-2/15 Demonstrates Superior Activity and Lower Toxicity thanIL-2 In Murine Melanoma Model B16 melanoma model in combination with mAb TA99 Survival Percent Source: Silva et al. Nature, 565,186-191 (2019) 14 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
Neo-2/15 Enhances CD8:Treg Ratio Naive mice • N =2-3 mice/group • Daily dosing x 14 days Source: Silva et al. Nature, 565,186-191 (2019) 15 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
Neo-2/15 Does Not Elicit Detectable Immunogenicity in Mice Sequence identity 14% by sequence alignment 29% by structural alignment Mice (N = 10/group) received intraperitonealNeo-2/15 ormIL-2, x14 days; 10mcg/day Source: Silva et al. Nature, 565,186-191 (2019) 16 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
NL-201 Improves on Nature: Designed to retain benefits ofIL-2 without drawbacks ✓ Hyperstable ✓ No binding to alpha chain ✓ Dual immune mechanisms ✓ Higher affinity activated binding than natural protein ✓ PotentIL-2 activation ✓ No bias toward ✓ PotentIL-15 activation endothelial cells orT-regulatory cells © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 17
IL-2/IL-15 Competitive Landscape Other significantIL-2/IL-15 immunotherapies in development are modified versions of nativeIL-2 orIL-15IL-2 modification often results in a less potent, less stable molecule, with some residual binding to the alpha subunit We believeNL-201 is the onlyIL-2 agonist specifically designed with no alpha-binding regionNL-201 potently agonizes bothIL-2 andIL-15 receptors, potentially stimulating complementary cancer-fighting pathways © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 18
NeoleukinTM Cytokine Mimetics are Hyperstable and Easily Modified Can use with targeting domain to improve biodistribution Able to adjust half-life or tune afinity Can be conditionally activated in the tumor microenvironment Able to withstand extreme conditions Can be modified to make cytokine antagonists for inflammatory and autoimmune diseases 19 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
NL-201: On Track for IND by End of 2020 CMC: process developed and GLP tox batch successfully produced Toxicology: multi-dose,non-GLP and GLP tox studies conducted in rats andnon-human primates â—‹ GLPin-life dosing complete; no unexpected toxicity observed Bioassays: GLP and clinical bioassays in development and on track to support IND submission and clinical studies Pharmacology: multiple models under evaluation 20 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce
Financial Highlights $66.3 million cash & cash equivalents as of Sept. 30, 2019Follow-on offering in December 2019 raised ~$81M (net) ~38 million common shares outstanding and ~11 millionpre-funded warrants afterfollow-on Cash and cash equivalents expected to fund operations through 2022 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 21
Upcoming Milestones Event Timeline Present Preclinical and Scientific Data 1H 2020 Submit IND forNL-201 By end of 2020 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce 22
life. 23 © 2020 Neoleukin Therapeutics. All Rights Reserved: Do not distribute or reproduce